FibroGen Inc (FGEN) concluded trading on Tuesday at a closing price of $0.50, with 2.22 million shares of worth about $1.11 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -52.13% during that period and on December 24, 2024 the price saw a gain of about 3.88%. Currently the company’s common shares owned by public are about 100.77M shares, out of which, 93.69M shares are available for trading.
Stock saw a price change of 45.07% in past 5 days and over the past one month there was a price change of 27.72%. Year-to-date (YTD), FGEN shares are showing a performance of -43.02% which decreased to -33.74% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.18 but also hit the highest price of $2.93 during that period. The average intraday trading volume for FibroGen Inc shares is 1.23 million. The stock is currently trading 29.61% above its 20-day simple moving average (SMA20), while that difference is up 38.68% for SMA50 and it goes to -40.65% lower than SMA200.
FibroGen Inc (NASDAQ: FGEN) currently have 100.77M outstanding shares and institutions hold larger chunk of about 45.77% of that.
The stock has a current market capitalization of $52.19M and its 3Y-monthly beta is at 0.80. It has posted earnings per share of -$1.23 in the same period. It has Quick Ratio of 1.16. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for FGEN, volatility over the week remained 14.08% while standing at 10.53% over the month.
Stock’s fiscal year EPS is expected to rise by 72.60% while it is estimated to increase by 43.12% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on August 08, 2023 offering an Underperform rating for the stock and assigned a target price range of between $4 and $2 to it. Stock get a Neutral rating from BofA Securities on June 26, 2023.
